In 2025, Pfizer and Viking Therapeutics faced challenges leading to underperformance, but both companies still offer potential growth opportunities. Pfizer’s clinical trials for PF-4404 show promise in cancer treatment, while Viking is developing a weight-loss medicine, VK2735, with positive results in phase 3 studies. Investors may find value in these stocks below $40.

Pfizer has struggled in recent years but is now focusing on clinical trials for cancer medicine PF-4404 and weight management asset MET-097i. The company’s diverse pipeline includes products in oncology, immunology, and vaccines, positioning it for future growth. Pfizer also secured a tariff exemption deal with the White House, boosting its long-term outlook.

Viking Therapeutics, a clinical-stage biotech, is developing the weight-loss medicine VK2735. The company’s multi-pronged approach includes oral and subcutaneous formulations to address weight maintenance challenges. Despite risks of setbacks, Viking’s stock could soar with solid clinical progress in the next few years. Investors should assess the potential rewards against the risks before investing.

The Motley Fool’s Stock Advisor team identified 10 best stocks for investors, excluding Pfizer. Past recommendations, like Netflix and Nvidia, have delivered significant returns. Stock Advisor’s total average return outperforms the S&P 500, offering investors a curated list of top-performing stocks. Don’t miss the latest recommendations to join a successful investing community.

Read more at Yahoo Finance: The Best Stocks to Invest $40 in to Start the New Year Off Right